Archive for March, 2011

March 15, 2011

Naturally Occurring Higher Hemoglobin Concentration Does Not Increase Mortality among Hemodialysis Patients

.   .   

This prospective, observational Dialysis Outcomes and Practice Patterns Study which examined 29,796 hemodialysis patients demonstrates and reassures that naturally occurring hemoglobin concentration >120 g/L is not associated with increased mortality. Free full text kindly provided by American Society of Nephrology.

Comments Off on Naturally Occurring Higher Hemoglobin Concentration Does Not Increase Mortality among Hemodialysis Patients Posted in Anemia
March 15, 2011

Antihypertensive Treatment and Secondary Prevention of Cardiovascular Disease Events Among Persons Without Hypertension: A Meta-analysis

.   .   

In this meta-analysis, antihypertensive treatment was associated with decreased risk of stroke, CHF, composite CVD events, and all-cause mortality in patients without hypertension, but with a clinical history of cardiovascular disease.

Comments Off on Antihypertensive Treatment and Secondary Prevention of Cardiovascular Disease Events Among Persons Without Hypertension: A Meta-analysis Posted in Hypertension, Vascular Disease/Calcification
March 15, 2011

Peritoneal Dialysis First: Rationale

.   .   

This review discusses factors that contribute to peritoneal dialysis underutilization and suggests strategies to implement PD as a first-line therapy for dialysis treatment.  In addition, it explores methods to maintain a strong PD program and avoid transfers to hemodialysis. Free full text kindly provided by the American Society of Nephrology.

1 Comment Posted in Peritoneal Dialysis
March 15, 2011

Kidney March

Walk 3 days. 100 kilometers. From K Country to Calgary. Raise $2,200 for the fight against kidney disease.  We are asking you to do the most you can possibly do – walk the furthest you’ve ever walked, raise the most money you’ve ever raised, and commit to truly making a difference. Walking 100 kilometres over […]

1 Comment Posted in Clinical Nephrology
March 15, 2011

Diuretic Strategies in Patients with Acute Decompensated Heart Failure

.   .   

Among patients with acute decompensated heart failure, there were no significant differences in global assessment of symptoms or in renal function when diuretic therapy was administered by bolus versus continuous infusion or at high dose verus low dose.

Comments Off on Diuretic Strategies in Patients with Acute Decompensated Heart Failure Posted in Internal Medicine for Nephrologists
March 15, 2011

Cardiovascular and Renal Outcomes With Telmisartan, Ramipril, or Both in People at High Renal Risk: Results From the ONTARGET and TRANSCEND Studies.

.   .   

This post hoc analysis examines the renal subgroups in the studies ONTARGET and TRANSCEND. The results do not support dual therapy over monotherapy in high-vascular risk patients with low glomerular filtration rate or albuminuria.

Comments Off on Cardiovascular and Renal Outcomes With Telmisartan, Ramipril, or Both in People at High Renal Risk: Results From the ONTARGET and TRANSCEND Studies. Posted in Chronic Kidney Disease, RAS Blockade
March 15, 2011

Bundled Payment for ESRD — Including ESAs in Medicare’s Dialysis Package

.   .   

This NEJM Perspective article discusses the implementation and implication of bundled Medicare reimbursement for ESRD therapy in the United States.

Comments Off on Bundled Payment for ESRD — Including ESAs in Medicare’s Dialysis Package Posted in Anemia, Hemodialysis, Peritoneal Dialysis
March 15, 2011

Special Treatment — The Story of Medicare’s ESRD Entitlement

.   .   

This historical review of the origins of ESRD coverage by the US Medicare program explains and summarizes how “…the moral cost of failing to provide lifesaving care was deemed to be greater than the financial cost of doing so.”

Comments Off on Special Treatment — The Story of Medicare’s ESRD Entitlement Posted in Hemodialysis
March 15, 2011

Switching from Calcineurin Inhibitor-based Regimens to a Belatacept-based Regimen in Renal Transplant Recipients: A Randomized Phase II Study

.   .   

This is another study assessing the role of belatacept, a costimulatory blocker in renal transplantation. As opposed to previous studies in de novo patients, this randomized controlled trial included patients 6 to 36 months post-transplant who continued on treatment with a calcineurininbitor or were switched to belatacept. There was a greater improvement in GFR after […]

Comments Off on Switching from Calcineurin Inhibitor-based Regimens to a Belatacept-based Regimen in Renal Transplant Recipients: A Randomized Phase II Study Posted in Renal Transplantation
March 15, 2011

Posttransplantation Encapsulating Peritoneal Sclerosis Contributes Significantly to Mortality after Kidney Transplantation

.   .   

Encapsulating peritoneal sclerosis is a rare but serious complication of peritoneal dialysis. It has also been reported as appearing after transplantation in patients who were on PD pre-transplant. This retrospective multicenter study shows that post-transplant EPS is associated with a high rate of mortality, and may present many years after transplantation.

Comments Off on Posttransplantation Encapsulating Peritoneal Sclerosis Contributes Significantly to Mortality after Kidney Transplantation Posted in Renal Transplantation
March 15, 2011

Long-Term Renal Allograft Survival in the United States: A Critical Reappraisal

.   .   

This study uses US transplant registry data to look at changes in both one-year and long-term graft survival post-transplant. This analysis shows that most of the improvement in recent years has been due to improvements in one-year graft survival. However, long-term graft loss rates have improved as well, although not as strikingly as short-term survival.

Comments Off on Long-Term Renal Allograft Survival in the United States: A Critical Reappraisal Posted in Renal Transplantation
March 15, 2011

Cardiovascular Disease Medications After Renal Transplantation: Results From the Patient Outcomes in Renal Transplantation Study

.   .   

Renal transplantation reduces the risk of cardiovascular events compared to dialysis, but these patients remain a high-risk group. This large international registry study shows that use of common cardioprotective agents such as antiplatelets agents, statins, beta-blockers, ACE-inhibitors and ARBs is lower than would be expected, although their use has increased over time. Whether increased use […]

Comments Off on Cardiovascular Disease Medications After Renal Transplantation: Results From the Patient Outcomes in Renal Transplantation Study Posted in Renal Transplantation, Vascular Disease/Calcification